PMID- 12015770
OWN - NLM
STAT- MEDLINE
DCOM- 20020613
LR  - 20201208
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 94
IP  - 9
DP  - 2002 May 1
TI  - Tumor vaccine for ovarian carcinoma targeting sperm protein 17.
PG  - 2447-53
AB  - BACKGROUND: The authors previously identified sperm protein 17 (Sp17) as being 
      expressed in patients with multiple myeloma. The restricted expression of Sp17 in 
      normal tissue makes it an ideal target for tumor vaccine. In the current study, 
      the authors extended their research to include ovarian carcinoma. METHODS: A pair 
      of sequence specific primers was used in reverse transcriptase-polymerase chain 
      reaction to determine the gene expression of Sp17. A recombinant Sp17 protein was 
      used with monocyte-derived dendritic cells and autologous peripheral blood 
      mononuclear cells to generate Sp17 specific cytotoxic T-lymphocytes (CTLs). The 
      successful generation of Sp17 specific CTLs was confirmed using standard 
      (51)chromium-release assays. RESULTS: Sp17 was found to be expressed in the 
      primary tumor cells from 70% of the patients with ovarian carcinoma. Human 
      leukocyte antigen (HLA) class I- restricted Sp17 specific CTLs were generated 
      successfully from the peripheral blood of three patients with ovarian carcinoma 
      at the time of disease presentation. These CTLs were able to lyse autologous 
      Epstein-Barr virus-transformed lymphoblastoid cells in a Sp17-dependent manner. 
      Target lysis was HLA class I-dependent and could be blocked by antibodies against 
      monomorphic HLA class I but not HLA class II molecules. The CTLs also lysed 
      Sp17-positive autologous tumor cells, suggesting that Sp17 is processed and 
      presented in association with the HLA class I molecules in Sp17- positive tumor 
      cells in a concentration and configuration that could be recognized by 
      recombinant protein-primed CTLs. Tumor cell killing by the CTLs appeared to be 
      mediated through the perforin pathway. Flow cytometric analysis of the CTLs 
      indicated that they predominantly were CD8 in phenotype and produced 
      interferon-gamma and scant amounts of interleukin-4. CONCLUSIONS: The results of 
      the current study suggest the potential of Sp17 as a target for immunotherapy in 
      patients with ovarian carcinoma.
CI  - Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10506
FAU - Chiriva-Internati, Maurizio
AU  - Chiriva-Internati M
AD  - Division of Hematology and Oncology, Texas Tech University School of Medicine at 
      Amarillo, USA.
FAU - Wang, Zhiqing
AU  - Wang Z
FAU - Salati, Emanuela
AU  - Salati E
FAU - Timmins, Patrick
AU  - Timmins P
FAU - Lim, Seah H
AU  - Lim SH
LA  - eng
GR  - R01 CA88434-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antigens, Surface)
RN  - 0 (Calmodulin-Binding Proteins)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Carrier Proteins)
RN  - 0 (Cytokines)
RN  - 0 (HLA Antigens)
RN  - 0 (Membrane Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (SPA17 protein, human)
SB  - IM
MH  - Antigens, Surface
MH  - Calmodulin-Binding Proteins
MH  - Cancer Vaccines/*immunology
MH  - Carrier Proteins/genetics/*immunology
MH  - Cytokines/analysis
MH  - Female
MH  - Flow Cytometry
MH  - HLA Antigens
MH  - Humans
MH  - Immunophenotyping
MH  - Membrane Proteins
MH  - Multiple Myeloma/immunology
MH  - Neoplasm Proteins/immunology
MH  - Ovarian Neoplasms/*immunology
MH  - Polymerase Chain Reaction
MH  - Recombinant Proteins/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
EDAT- 2002/05/17 10:00
MHDA- 2002/06/14 10:01
CRDT- 2002/05/17 10:00
PHST- 2002/05/17 10:00 [pubmed]
PHST- 2002/06/14 10:01 [medline]
PHST- 2002/05/17 10:00 [entrez]
AID - 10.1002/cncr.10506 [doi]
PST - ppublish
SO  - Cancer. 2002 May 1;94(9):2447-53. doi: 10.1002/cncr.10506.